Trial reportScientific reports2026
The impact of vaginal bromocriptine on reducing pain and menstrual bleeding in women with adenomyosis: a randomized controlled trial.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bromocriptine, a dopamine receptor agonist that suppresses prolactin secretion from the pituitary gland, is an inexpensive and widely accessible medication with few adverse effects. The study aim was to assesse the efficacy of vaginal bromocriptine in reducing pelvic pain, menstrual bleeding, and cycle irregularities among patients with adenomyosis. In this randomized controled trial, 64 women diagnosed with adenomyosis were randomly assigned to either an intervention group receiving vaginal bromocriptine or a routine-treatment group. The intervention consisted of 5 mg bromocriptine administered vaginally once daily for three months. The control group received standard treatment comprising oral contraceptive pills (OCPs) and mefenamic acid. Primary outcome measures were menstrual bleeding volume, pain intensity, and menstrual cycle regularity. Linear regression models were used to evaluate changes in menstrual bleeding after adjusting for potential confounders. All 64 participants (32 per group) completed the study and were included in the analysis. Baseline demographic, obstetric, and ultrasonographic characteristics were comparable between groups (P > 0.05). After treatment, the mean pain score was significantly lower in the intervention group than in the control group (2.01 vs. 5.10; P = 0.011). Mean menstrual bleeding volume also decreased significantly with vaginal bromocriptine (280.8 mL vs. 525.9 mL; P = 0.001). Final analysis indicated that bromocriptine significantly reduced menstruation bleeding after adjusting for potential confounders (Beta= - 1.157, P = 0.001). Vaginal bromocriptine appears to be an effective and well-tolerated therapeutic option for alleviating symptoms of adenomyosis, particularly pelvic pain, excessive menstrual bleeding, and irregular cycles. The beneficial effects may result from reduced prolactin levels, inhibition of angiogenesis, and modulation of the hypothalamic-pituitary-ovarian axis.Trail registration number IRCT20240806062668N3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.